Polygenic Score (PGS) ID: PGS005241

Predicted Trait
Reported Trait Prostate carcinoma
Mapped Trait(s) prostate carcinoma (EFO_0001663)
Released in PGS Catalog: Oct. 6, 2025
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name SBayesRC
Development Method
Name SBayesRC
Parameters SBayesRC extends SBayesR by incorporating functional annotations, enabling the joint analysis of all common SNPs across the genome. It utilises a multicomponent annotation-dependent mixture prior to more accurately model the distribution of SNP effects, allowing it to estimate both annotation parameters and SNP effects. SBayesRC does not require a tuning cohort.
Variants
Original Genome Build GRCh37
Number of Variants 3,802,635
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000741
Citation (link to publication) Tanha HM et al. HGG Adv (2025)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 75.8%
East Asian: 11.7%
African: 9.1%
Hispanic or Latin American: 3.4%
234,253 individuals (100%)
PGS Evaluation
European: 60%
African: 20%
South Asian: 20%
5 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST011049
Europe PMC: 33398198
 177,526 individuals European NR
GWAS Catalog: GCST011049
Europe PMC: 33398198
 21,354 individuals African American or Afro-Caribbean,African unspecified NR
GWAS Catalog: GCST011049
Europe PMC: 33398198
 27,420 individuals East Asian NR
GWAS Catalog: GCST011049
Europe PMC: 33398198
 7,953 individuals Hispanic or Latin American NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM022674 PSS012056|
European Ancestry|
184,010 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.644 [0.634, 0.653] — - —
PPM022679 PSS012055|
African Ancestry|
3,193 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.55 [0.483, 0.616] — - —
PPM022689 PSS012054|
European Ancestry|
6,791 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.64 [0.606, 0.674] — - —
PPM022694 PSS012053|
European Ancestry|
1,809 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.694 [0.663, 0.725] — - —
PPM022699 PSS012056|
European Ancestry|
184,010 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.758 [0.751, 0.766] — Age-specific absolute risk adjusted by PGS relative risk —
PPM022704 PSS012057|
South Asian Ancestry|
5,097 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.805 [0.743, 0.868] — Age-specific absolute risk adjusted by PGS relative risk —
PPM022709 PSS012055|
African Ancestry|
3,193 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.788 [0.747, 0.829] — Age-specific absolute risk adjusted by PGS relative risk —
PPM022714 PSS012054|
European Ancestry|
6,791 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.689 [0.661, 0.718] — Age-specific absolute risk adjusted by PGS relative risk —
PPM022719 PSS012053|
European Ancestry|
1,809 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.705 [0.675, 0.736] — Age-specific absolute risk adjusted by PGS relative risk —
PPM022684 PSS012057|
South Asian Ancestry|
5,097 individuals
 PGP000741 |
Tanha HM et al. HGG Adv (2025)
 Reported Trait: 5-year incident prostate cancer — AUROC: 0.594 [0.486, 0.703] — - —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS012053 Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. —
[
  • 327 cases
  • , 1,482 controls
]
,
100.0 % Male samples
 European PC1-PC4 values ±3s.d. from the 1000G European cluster MCCS MCCS had a case/sub-cohort design, leading to a higher proportion of cases
PSS012054 Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. —
[
  • 269 cases
  • , 6,522 controls
]
,
100.0 % Male samples
 European PC1-PC4 values ±3s.d. from the 1000G European cluster QSKIN —
PSS012055 Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. —
[
  • 82 cases
  • , 3,111 controls
]
,
100.0 % Male samples
 African American or Afro-Caribbean AFR individuals were identified by PC1-PC4 from 1000G and k-means clustering. UKB —
PSS012056 Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. —
[
  • 3,133 cases
  • , 180,877 controls
]
,
100.0 % Male samples
 European EUR individuals were identified by PC1-PC4 from 1000G and k-means clustering. UKB —
PSS012057 Linked cancer registry records were used to identify participants diagnosed with incident malignant neoplasm of the prostate (ICD-10 code: C61; ICD-9 code: 185) within five years of prediction baseline. —
[
  • 30 cases
  • , 5,067 controls
]
,
100.0 % Male samples
 South Asian SAS individuals were identified by PC1-PC4 from 1000G and k-means clustering. UKB —